Radiopharm Theranostics Ltd
RADX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001949257
No open-market purchases or sales by Radiopharm Theranostics Ltd insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $1.18M in total; no superinvestor holds it.
Other share classesRDPTF
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 6
- 13F valueReported value at the end of Q2 2026
- $1.18M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RADX, Q2 2026
No superinvestor reported holding RADX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Radiopharm Theranostics Ltd insiders from Form 4, newest first.
No open-market purchases or sales by Radiopharm Theranostics Ltd insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Radiopharm Theranostics Ltd at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 51,000,000 | $670.5K | 0.51% | 00.0% | Unchanged |
| HSBC Holdings PLC | 62,188 | $253.7K | 0.00% | +816+1.3% | Added |
| VGI Partners Ltd | 40,138 | $168.2K | 0.01% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 20,000 | $83.8K | 0.00% | +4,000+25.0% | Added |
| UBS Group AG | 1,507 | $6.31K | 0.00% | −1,493−49.8% | Reduced |
| Rhumbline Advisers | 195 | $817 | 0.00% | +74+61.2% | Added |